These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35716420)

  • 21. Identification and characterization of degradation products of indacaterol using liquid chromatography/mass spectrometry.
    Yerra NV; Dadinaboyina SB; Vigjna Abbaraju L; Kumar Talluri M; Reddy Thota J
    Eur J Mass Spectrom (Chichester); 2020 Dec; 26(6):425-431. PubMed ID: 33153322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LC-MS/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway.
    Grover P; Bhardwaj M; Mehta L
    J Pharm Biomed Anal; 2021 Nov; 206():114351. PubMed ID: 34509659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of degradation products of tegoprazan by LC-MS and GC-MS.
    Guo K; He X; Zhao H; Ma C
    J Pharm Biomed Anal; 2023 May; 228():115323. PubMed ID: 36921447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and characterization of forced degradation products of 5-hydroxymethyl-2-furaldehyde (5-HMF) by HPLC, LC-LTQ/Orbitrap and NMR studies.
    Lu Y; Guo Y; Zhang Y; Sun H; Wu X
    J Pharm Biomed Anal; 2023 Sep; 233():115470. PubMed ID: 37210891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of stability-indicating assay method and liquid chromatography-quadrupole-time-of-flight mass spectrometry-based structural characterization of the forced degradation products of alpelisib.
    Ghanghav V; Chawathe A; Chauthe SK; Sharma N
    Biomed Chromatogr; 2024 Mar; 38(3):e5813. PubMed ID: 38148302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products.
    Thummar M; Kuswah BS; Samanthula G; Bulbake U; Gour J; Khan W
    J Pharm Biomed Anal; 2018 Oct; 160():89-98. PubMed ID: 30075398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromatographic separation of tiropramide hydrochloride and its degradation products along with their structural characterization using liquid chromatography quadrupole time-of-flight tandem mass spectrometry and nuclear magnetic resonance.
    Tidke M; Golla VM; Kushwah BS; Naik DD; Gananadhamu S
    Biomed Chromatogr; 2023 Aug; 37(8):e5636. PubMed ID: 37005769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry.
    Rajput N; Soni F; Sahu AK; Jadav T; Sharma S; Sengupta P
    J Pharm Biomed Anal; 2022 Jun; 215():114753. PubMed ID: 35447490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of stress degradation products of fosinopril by using LC-MS/TOF, MS(n) and on-line H/D exchange.
    Narayanam M; Singh S
    J Pharm Biomed Anal; 2014 Apr; 92():135-43. PubMed ID: 24518132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Method validation and characterization of stress degradation products of azelastine hydrochloride using LC-UV/PDA and LC-Q/TOF-MS studies.
    Shekhar S; Bali A
    Rapid Commun Mass Spectrom; 2024 Apr; 38(7):e9712. PubMed ID: 38351666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural characterization and in silico toxicity prediction of degradation impurities of roxadustat.
    Mahajan R; Kumar S; Parupalli R; Khemchandani R; Kanchupalli V; Nanduri S; Samanthula G; Asthana A
    J Pharm Biomed Anal; 2023 Sep; 234():115517. PubMed ID: 37320975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of degradation behaviour of montelukast sodium and its marketed formulation in oxidative and accelerated test conditions and prediction of physicochemical and ADMET properties of its degradation products using ADMET Predictor™.
    Tiwari SK; Singh DK; Ladumor MK; Chakraborti AK; Singh S
    J Pharm Biomed Anal; 2018 Sep; 158():106-118. PubMed ID: 29864693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comprehensive forced degradation studies of Cariprazine hydrochloride using LC-HRMS/MS and in silico toxicity predictions of its degradation products.
    Jain M; Khan S
    J Pharm Biomed Anal; 2022 Sep; 219():114955. PubMed ID: 35917732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification, characterisation and in silico ADMET prediction of ozenoxacin and its degradation products using high-performance liquid chromatography-photodiode array and liquid chromatography-quadrupole time-of-flight-tandem mass spectrometry.
    Matta A; Sundararajan R
    Rapid Commun Mass Spectrom; 2024 Feb; 38(3):e9676. PubMed ID: 38211348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of degradation products and process-related impurity of sutezolid by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Guo K; Zhang T; Wang Y; Jin B; Ma C
    J Pharm Biomed Anal; 2019 May; 169():196-207. PubMed ID: 30877931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stress degradation studies on lornoxicam using LC, LC-MS/TOF and LC-MSn.
    Modhave DT; Handa T; Shah RP; Singh S
    J Pharm Biomed Anal; 2011 Nov; 56(3):538-45. PubMed ID: 21757313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of omarigliptin forced degradation products by ultra-fast liquid chromatography, mass spectrometry, and in vitro toxicity assay.
    Mohr A; de Souza Barbosa F; Wingert NR; Takeuchi CK; Garcia L; Ribeiro MFN; Arbo MD; de Oliveira TF; Steppe M
    Biomed Chromatogr; 2024 Aug; 38(8):e5904. PubMed ID: 38811368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Forced degradation study of racecadotril: Effect of co-solvent, characterization of degradation products by UHPLC-Q-TOF-MS/MS, NMR and cytotoxicity assay.
    Chiguru V; Lingesh A; R S; N S
    J Pharm Biomed Anal; 2016 Sep; 128():9-17. PubMed ID: 27209450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification, characterization, and in silico ADMET prediction of nirmatrelvir and its degradation products using HPLC-PDA and LC-QTOF-MS/MS.
    Kumar MA; Sundararajan R
    Rapid Commun Mass Spectrom; 2024 Oct; 38(20):e9896. PubMed ID: 39185574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification, characterization and in silico ADMET prediction of Roflumilast degradation products.
    Pinheiro MS; Viana GM; Vieira BA; de Souza AM; Rodrigues CR; Marins RC; Cabral LM; de Sousa VP
    J Pharm Biomed Anal; 2017 May; 138():126-133. PubMed ID: 28196344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.